As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
When outcome selection and prioritisation are defined early in development, the evidence base supports continuity from trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results